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Abstract
Introduction Studies on the blood pressure lowering
effect of renal denervation (RDN) in resistant hypertensive
patients have produced conflicting results. Change in
medication usage during the studies may be responsible for
this inconsistency. To eliminate the effect of medication
usage on blood pressure we focused on unmedicated
hypertensive patients who underwent RDN.
Methods and results Our study reports on a cohort of
patients, who were not on blood pressure lowering drugs at
baseline and during follow-up, from eight tertiary centers.
Data of patients were used when they were treated with
RDN and had a baseline office systolic blood pressure
(SBP) C140 mmHg and/or 24-h ambulatory SBP C
130 mmHg. Our primary outcome was defined as change
in office and 24-h SBP at 12 months after RDN, compared
to baseline. Fifty-three patients were included. There were
three different reasons for not using blood pressure low-
ering drugs: (1) documented intolerance or allergic reaction
(57 %); (2) temporary cessation of medication for study
purposes (28 %); and (3) reluctance to take antihyperten-
sive drugs (15 %). Mean change in 24-h SBP was
-5.7 mmHg [95 % confidence interval (CI) -11.0 to
-0.4; p = 0.04]. Mean change in office SBP was
-13.1 mmHg (95 % CI -20.4 to -5.7; p = 0.001). No
changes were observed in other variables, such as eGFR,
body–mass-index and urinary sodium excretion.
Conclusion This explorative study in hypertensive
patients, who are not on blood pressure lowering drugs,
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suggests that at least in some patients RDN lowers blood
pressure.
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Introduction
Sympathetic overactivity and kidney injury are major con-
tributors in sustaining high blood pressure (BP) levels [1].
Percutaneous renal denervation (RDN) of the sympathetic
nerves surrounding the renal arteries has been introduced as
a therapy for (resistant) hypertension [2, 3]. Several studies
have shown a reduction in ambulatory systolic blood pres-
sure (SBP) ranging from 5 to 10 mmHg at 6- to 12-month
follow-up after RDN [2, 4–6]. In the Symplicity HTN-3
trial, no difference in BP change between RDN-treated
patients and the sham-treated control group was reported [7].
This has greatly fueled the discussion on the role of RDN as
an antihypertensive treatment. Technical and procedural
insufficiency may have hampered the proof of an antihy-
pertensive effect of RDN [8]. In addition, it has been argued
that the effects in earlier studies could be attributed to
regression to the mean, improvement in lifestyle factors and,
in particular, to a change in medication use [9–11]. In the
Symplicity HTN-3 study, substantial differences in baseline
anti-hypertensive medications and a striking 40 % change in
prescribed anti-hypertensives in both control and RDN-
treated groups during the study has seriously limited eval-
uation of the true effect of RDN [7]. Furthermore it is now
well recognized that drug adherence in patients with
hypertension is highly variable which further complicates
assessment of anti-hypertensive effects of drugs or device
therapy [12–14]. Recent RDN trials have attempted to
overcome this problem by witnessed medication intake or by
applying adherence questionnaires [6, 7, 15]. In these ran-
domized controlled trials, the effect of RDN on 24-h SBP
ranged from no change to a reduction of 6 mmHg, with
comparable medication adherence in RDN treated patients
and the control group. Hypertensive patients on no medi-
cation seem to be an ideal population to quantify the effect
of RDN on BP. Furthermore, patients with intolerance of
anti-hypertensive medication pose a major challenge to
clinicians and novel approaches are needed to improve their
BP control given their high cardiovascular risk [16]. This
study reports on a collaborative initiative of eight centers
active in device based therapy for hypertension. We present
the results of RDN in hypertensive patients who used no
blood pressure lowering drugs for their BP before RDN and
during follow-up.
Methods
Design and study population
The study was designed to evaluate a cohort of patients that
underwent RDN and who were either without blood pres-
sure lowering drugs at baseline and follow-up, or, whose
medication was withdrawn according to protocol. Our
primary outcome was defined as change in office and 24-h
SBP at 12 months after RDN, compared to baseline. Eight
international centers (seven in Europe and one in Australia)
participated in this initiative (Table 4, Supplemental Dig-
ital Content, which represents the participating centers).
These centers delivered patient records that met the fol-
lowing inclusion criteria: the patient was C18-year-old,
treated with catheter-based RDN and had a baseline office
SBP C140 mmHg and/or 24-h SBP C130 mmHg. Patients
were excluded if they were using medication for their
hypertension or when no BP data were available at baseline
or during follow-up visits. Local medical ethics committees
approved the primary study in which the patient originally
participated, in accordance with the Declaration of
Helsinki.
Blood pressure assessments
Twenty-four-hour BP and office BP measurements were
collected at baseline and at 6 months and/or 12 months
post RDN. Twenty-four-hour BP was calculated as the
mean of the readings at least every 30 min at daytime and
every hour at nighttime. Office BP was calculated as the
mean of three measurements obtained with a noninvasive
automatic blood pressure measuring device with at least
5 min resting between each BP reading. All BP measure-
ments were performed in accordance with the European
guidelines and with recommended devices [17, 18]. In the
absence of a control group, we compared our results with
the possible BP lowering effect of simply taking part in a
study. To assess this potential placebo effect, we selected
studies from a recently published systematic review by
Patel and co-workers (Fig. 2, Supplemental Digital Con-
tent, represents a forest plot of the selected studies) [19].
Other assessments
We collected physical (e.g., height, weight) and biochem-
ical parameters (e.g., urinary sodium excretion) to explore
lifestyle and other potentially relevant factors at baseline
and follow-up. We report on body mass index, kidney
function and 24-h urinary sodium excretion. Serum crea-
tinine was determined as standard care at each study site
(Jaffe´ or Enzymatic method). The estimated glomerular
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filtration rate (eGFR) was calculated using the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI)
or Modification of Diet in Renal Diseases (MDRD) equa-
tion [20, 21]. Measurements were standardized by con-
verting the creatinine measurements with the Jaffe´ method
to the Enzymatic method and the eGFR with MDRD to the
CKD-EPI estimation.
RDN procedure
Study sites selected patients for RDN according to their
own study protocol (Table 4, Supplemental Digital Con-
tent, which represents the participating centers). Percuta-
neous radiofrequency ablation was performed with
SymplicityTM catheter (Medtronic Inc., Santa Rosa, Cali-
fornia) or EnligHTNTM Ablation catheter (St Jude Medical,
St Paul, MN, USA). Ultrasound RDN was performed with
the use of PARADISETM technology (ReCor Medical,
Ronkonkoma, NY, USA). The treating physician decided
which renal arteries to treat, which device to use and how
many ablations could be performed.
Statistical analysis
Results are presented as the mean difference between
baseline and 12 months with corresponding standard error
and 95 % CI interval, unless otherwise stated. When the
95 % CI does not contain the zero value, the difference is
considered statistically significant. Our primary outcome
was change in BP 12 months after RDN. For missing data,
we used the 6-month BP data carried forward. The ratio-
nale for this approach was to increase the number of
individuals with an outcome variable. This was considered
to be reasonable based on previous reports showing that
over time the magnitude of the RDN effect does not seem
to attenuate between 6 and 12 months, if anything an
increase in RDN effect is expected [5, 22]. To study the
mean changes in BP we used paired analyses. To study
change in BP and change in biological variables after
RDN, we applied a linear regression model. Also, a linear
regression model was applied to explore which baseline
factors were related to the blood pressure change. Uni-
variable models were the main approach due to the small
sample size. To explore the data further, we applied a one-
way ANOVA model to determine whether the reason for
not using blood pressure lowering drugs resulted in dif-
ferent BP changes. In the present study we aimed to collect
results of as many individuals as possible, who underwent
RDN and were not using blood pressure lowering drugs.
Therefore, no sample size estimation was done upfront. All
analyses were performed using the IBM SPSS Statistics for
Windows, Version 21.0 (IBM Corp., Armonk, NY, USA).
Results
Baseline characteristics
Fifty-three records of patients, who complied with our
inclusion criteria, were included. There were three different
reasons for not using BP lowering drugs: (1) documented
intolerance or allergic reaction (57 %); (2) temporary
cessation of medication for study purposes (followed by
immediate resumption of drug treatment after study visits),
using a highly standardized stepwise program (28 %); and
(3) reluctance to take antihypertensive drugs (15 %) [23,
24]. Four patients for whom the reason was unknown were
included in the first group. All patients underwent RDN
between May 2011 and August 2014 in different study
settings (Table 4, Supplemental Digital Content). Baseline
characteristics are summarized in Table 1. Mean baseline
24-h BP was 160 ± 17/94 ± 11 mmHg and mean office
BP was 180 ± 24/101 ± 14 mmHg. Mean baseline eGFR
estimated by CKD-EPI was 85 ± 18 ml/min/1.73 m2.
Three patients (6 %) had moderately reduced kidney
function (eGFR\60 ml/min/1.73 m2). Forty-two patients
were treated with the Symplicity catheter, ten with the
EnligHTN catheter and one was treated with ultrasound
RDN. Baseline characteristics of the three groups of
patients, according to the reason for not using blood pres-
sure lowering drugs, are shown in Table 5 (Supplemental
Digital Content).
Change in blood pressure
Twenty-four-hour BP and office BP data were available in
43 and 47 patients, respectively (6-month office and 24-h
BP data were carried forward for 7 and 14 patients,
respectively). In the whole group, 24-h SBP and diastolic
BP (DBP) reduced after RDN as compared to baseline by
-5.7 mmHg [95 % confidence interval (CI), -11.0 to
-0.4; p = 0.04] and -4.0 mmHg (95 % CI -6.6 to -1.4;
p = 0.003), respectively. Office SBP and DBP decreased
significantly after RDN by -13.1 mmHg (95 % CI -20.4
to -5.7; p = 0.001) and -4.4 mmHg (95 % CI -7.8 to
-1.1; p = 0.01), respectively (Table 2). There were no
statistically significant differences in BP change between
the three groups (p = 0.45 and p = 0.93 for 24-h SBP and
office SBP, respectively) (Table 6, Supplemental Digital
Content). BP changes at 6 and 12 months are separately
presented in Table 7 (Supplemental Digital Content).
Based on a systematic review, a selective pooling of pre-
vious studies was performed to assess the effect of par-
ticipating in a trial on BP levels. Mean change in office
SBP in the placebo controlled group was -4.0 mmHg
(95 % CI -7.5 to -0.4) and the change in 24-h SBP
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-0.9 mmHg (95 % CI -2.1 to 0.2) (Fig. 2, Supplemental
Digital Content, which represents a forest plot of the
selected studies).
Anatomic and procedural determinants
Renal artery anatomy was established in 50 patients.
Thirty-seven patients had a solitary artery on both sides, 13
patients had accessory renal arteries on one or both sides,
of which three patients had more than one. Patients with
solitary renal arteries were all treated in both renal arteries.
Of the patients having accessory renal arteries, seven
patients could not be treated in all renal arteries. In Fig. 1,
the individual changes in BP are presented for the patients
with solitary renal arteries. Mean change in 24-h SBP is
-5.4 mmHg (95 % CI -10.7 to -0.11) and mean change
in office SBP is -18.5 mmHg (95 % CI -26.7 to -10.4).
Individual changes of the patients with accessory renal
arteries are shown in Fig. 3 (Supplemental Digital Con-
tent). Change in 24-h SBP and office SBP did not differ
between groups based on the device (Symplicity and
EnligHTN) used for RDN (p = 0.56; p = 0.87, respec-
tively). There was no relation between the number of
ablations and the change in 24-h SBP and office SBP
(p = 0.97; p = 0.71, respectively). Data are not shown in
this article.
Explorative analyses into determinants of response
to RDN
Univariable analysis showed no significant relation
between baseline 24-h SBP and change in 24-h SBP after
RDN [mean change in 24-h SBP is -0.22 mmHg (95 % CI
-0.53 to 0.083; p = 0.15) for every mmHg increase in
baseline 24-h SBP]. There was a significant relation
between baseline office SBP and change in SBP after RDN
(mean change in office SBP is -0.36 mmHg (95 % CI
-0.64 to -0.089; p = 0.011) for every mmHg increase in
baseline office SBP).We observed a relation between per-
centage dipping at baseline and change in SBP after RDN
[mean change in 24-h SBP is 0.76 mmHg (95 % CI 0.18 to
1.35; p = 0.01) and for office SBP 0.82 mmHg (95 % CI
0.013 to 1.62; p = 0.047] for every percentage increase in
dipping (Fig. 4, Supplemental Digital Content, which
represents the relation between these variables). This
demonstrates that patients with more nocturnal dipping
have less reduction in blood pressure after RDN. Further-
more, nighttime BP was positively related to change in
SBP after RDN [mean change in 24-h SBP is
-0.43 mmHg (95 % CI -0.70 to -0.16; p = 0.002) and
for office SBP -0.35 mmHg (95 % CI -0.74 to -0.054;
p = 0.088) for every percentage increase in nighttime BP].
All univariable analyses are presented in Table 3. With
regard to lifestyle and other biological factors, we observed
no changes in BMI, eGFR and urinary sodium excretion
after RDN (Table 2).
Discussion
To the best of our knowledge, this is the first report on the
BP lowering effect of RDN in hypertensive patients who
were not using blood pressure lowering drugs at baseline
and during follow-up. Ambulatory and office BP were
Table 1 Baseline characteristics of the study population
All patients (n = 53)
Age (years)a 62 (35–80)
Gender (male)b 24 (45.3)
Caucasianb 53 (100)
Body mass index 28.4 (±4.9)
Comorbidity
Dyslipidemiab 36 %
Diabetes Mellitus type 2b 11 %
Cardiovascular diseasesb 15 %
Cerebrovascular diseasesb 6 %
Current smokingb 4 (8)
Nr. of antihypertensive drugsa 0 (0–0)
Reason for no medication use
Intolerance, unknownb 30 (57)
Study purposesb 15 (28)
Never prescribedb 8 (15)
Office blood pressure
Systolic (mmHg) 180 (±24)
Diastolic (mmHg) 101 (±14)
Heart rate (bpm) 72 (±10)
Ambulatory blood pressure
24-h systolic (mmHg) 160 (±17)
24-h diastolic (mmHg) 94 (±11)
24-h heart rate (bpm) 72 (±9)
eGFR, CKD epi (mL/min/1.73 m2) 85 (±18)
Presence of accessory renal arteriesb 13 (25)
Not all renal arteries treatedb 7 (15)
Device used
Symplicityb 42 (79)
EnligHTNb 10 (19)
PARADISEb 1 (2)
Nr. of ablationsa 13 (2–25)
Data are expressed as mean ± SD, unless stated otherwise
Body mass index is the weight in kilograms divided by the square of
the height in meters
Bpm beats per minute, eGFR estimated glomerular filtration rate
a Data are mean (range)
b Data are n (%) or percentage
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significantly reduced after RDN, in this patient group with
considerable heterogeneity. So far, the effect of RDN has
been investigated when added to medical therapy in
patients with so called resistant hypertension. Resistant
hypertension is defined as an office SBP C140 mmHg,
despite the use of at least three BP lowering drugs [17]. A
major difficulty in such studies is that use of prescribed
medication is highly variable and, importantly, may change
over time. In the present study, this poorly controllable, but
important effect modifier, has been eliminated by selecting
patients not on antihypertensive drugs, allowing an esti-
mation of the net effect of RDN. The magnitude of the
RDN effect seen in our study is comparable to what has
been documented in the DENERHTN study, in which the
BP lowering efficacy of RDN plus standardized antihy-
pertensive treatment was compared with standardized
antihypertensive treatment alone in patients with resistant
hypertension. In DENERHTN specific efforts were
undertaken to maximize medication adherence [6]. When
looking at 6-months results, they noted a change in 24-h BP
of -5.9/-3.1 mmHg which is not very different from the
-5.0/-2.0 mmHg we found in our study. In addition, we
found a further decline to -7.0/-4.0 mmHg 12 months
after RDN. As mentioned above, we observed considerable
Table 2 Change in blood
pressure and other relevant
parameters after RDN
N Mean change compared to baseline (95 % CI)
Ambulatory blood pressure
24-h systolic (mmHg) 43 -5.7 (-11.0 to -0.4)
24-h diastolic (mmHg) 43 -4.0 (-6.6 to -1.4)
24-h heart rate (bpm) 35 -1.1 (-3.8 to 1.7)
Day-time systolic (mmHg) 39 -8.2 (-13.4 to -3.0)
Day-time diastolic (mmHg) 39 -4.9 (-7.9 to -2.5)
Nighttime systolic (mmHg) 38 -6.3 (-14.1 to 1.4)
Nighttime diastolic (mmHg) 38 -4.8 (-9.9 to 0.4)
Office blood pressure
Systolic (mmHg) 47 -13.1 (-20.4 to -5.7)
Diastolic (mmHg) 47 -4.4 (-7.8 to -1.1)
Heart rate (bpm) 25 -2.6 (-6.7 to 1.5)
Body mass index (kg/m2) 25 0.5 (-0.9 to 1.9)
eGFR, CKD epi (mL/min/1.73 m2) 48 0.4 (-1.9 to 2.8)
Urinary sodium excretion (mmol/24 h) 16 -23.3 (-89.3 to 42.7)
N represents the number of patients with information on the variable of interest at baseline and at follow-up
Body mass index is the weight in kilograms divided by the square of the height in meters
Bpm beats per minute, eGFR estimated glomerular filtration rate
Fig. 1 Individual changes in blood pressure after RDN, in patients with solitary renal arteries a, n = 35 and b, n = 34. SBP systolic blood
pressure
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heterogeneity of BP response to RDN. This variability was
also noted in previous studies [6, 22]. Procedure and
patient related factors could play a role. The majority of the
renal denervation procedures were done with Medtronic’s
Simplicity device. It is now increasingly clear that proce-
dural factors such as completeness of circumferential
coverage, depth and location of ablations may result in a
variable and unpredictable degree of nerve destruction and
as result a variable effect on BP [25, 26]. In this small study
sample, we found no relation between the number of
ablations and BP effect and no difference in effect between
the two devices. Explorative analyses were performed on
patient related factors that may affect the degree of effect.
As consistently reported earlier, we found that a higher
baseline office SBP is associated with a larger BP reduction
[22, 27, 28]. Interestingly, the BP lowering effect was
larger in non-dipping patients. This finding is in line with
the knowledge that reduced nocturnal dipping is a char-
acteristic of an upregulated sympathetic nervous system
[24]. Furthermore, a comparable relation between night-
time BP and reduction in BP was seen.
For this study, we collected records of patients previ-
ously treated with RDN, therefore a control group was
lacking. This results in uncertainty whether the observed
decline in BP after RDN may (partially) be due to other
mechanisms, including lifestyle improvement, the effect of
taking part in a trial and also the ‘regression to the mean’
phenomenon. Our data suggest no major changes in
potentially relevant factors, such as BMI, eGFR and uri-
nary sodium excretion. It is highly implausible that ‘re-
gression to the mean’ can be responsible when observing
sustained BP reductions 12 months post RDN. Further-
more, most patients already have a long history of hyper-
tension. To overcome the limitation of having no control
group, we assessed the BP lowering effect in the placebo
arm of hypertension trials in patient populations not on
antihypertensive drugs, based on a recently published
systematic review. (Figure 2, Supplemental Digital Con-
tent) [19, 29–38]. The comparison of this estimated pla-
cebo effect with the present analysis suggests that the 24-h
and office BP reduction after RDN (-5.7 and
-13.0 mmHg systolic, respectively) is on average larger
than could be expected from participating in a study per se
(-0.9 and -4.0 mmHg change in SBP, respectively).
Although, we believe this is the best available comparison,
an important limitation is the heterogeneity of these studies
and, on average, lower baseline BP compared with our
study. Furthermore, the calculated study-/placebo effect
was purely based on pharmacological interventions. The
effect of a sham procedure might be different.
This study has some other limitations as well. Firstly,
our study may consist of a highly selected population.
However, when compared to earlier studies, our population
did not differ in mean levels of predictors of response to
RDN [6, 7, 15, 22, 39]. Therefore, our results unlikely
reflect a biased estimate. Secondly, we did not measure
drug metabolites to check whether patients were really not
using blood pressure medication during the measurement.
However, it seems unlikely that patients are using drugs
without prescription.
Conclusion
In conclusion, this explorative study suggests a beneficial
effect of RDN on blood pressure in patients with hyper-
tension, independent of medication change during the
study. Furthermore, this supports the rationale to investi-
gate the effects of RDN in a patient population not on
blood pressure lowering drugs [40, 41].
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